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Abstract
Background: Chronic musculoskeletal pain (CMP) in adolescents can influence functioning and well-being, and has
negative consequences for families and society as well. According to the Fear Avoidance Model, fear of movement
and pain catastrophizing can influence the occurrence and maintenance of chronic pain complaints and functional
disability. Primary objective is to evaluate the effectiveness of a multimodal rehabilitation program in reducing
functional disability for adolescents with CMP compared with care as usual.
Methods/Design: Pragmatic multicentre parallel group randomized controlled trial. Randomization by minimization
(ratio 1:1) and treatment allocation will be concealed, computer-generated and performed by an independent
organization. After randomization, data collection and researchers remain blinded. Inclusion of 124 adolescents and
their parents is intended. This sample size is based on a 25 % difference in group mean on the primary outcome,
with α = 5 %, β = 80 % and expected 15 % loss to follow up. Study population are adolescents (12–21 years) with
CMP with an indication for outpatient rehabilitation treatment in the Netherlands.
The intervention group receives a Multimodal Rehabilitation Program (MRP), a multidisciplinary outpatient individual
rehabilitation program. MRP consists of 2 different treatment approaches: A graded exposure module or a
combination module of graded exposure and physical training. Selection of a module depends on the needs of the
patient. To both modules a parent module is added. The control group receives care as usual, which is the care
currently provided in Dutch rehabilitation centres. Treatment duration varies between 7 and 16 weeks, depending
on treatment allocation.
Self-reported measurements are at baseline, and at 2, 4, 10 and 12 months after start of treatment. Intention to
treat analysis for between group differences on all outcome variables will be performed. Primary outcome is
functional disability (Functional Disability Inventory). Secondary outcome variables are fear of pain, catastrophizing,
perceived harmfulness, pain intensity, depressive symptoms, and quality of life. Total direct and indirect costs
and health related quality of life will be measured. Process evaluation focuses on protocol adherence, patient
centeredness and treatment expectations.
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Discussion: A pragmatic approach was chosen, to ensure that results obtained are most applicable to daily
practice.
Trial registration: Clinicaltrials.gov ID: NCT02181725 (7 February 2014).
Funded by Fonds Nuts Ohra, Stichting Vooruit, and Adelante.
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Background
Chronic pain in children and adolescents is a major
health concern in the paediatric population [1–3]. Up to
25 % of Dutch schoolchildren, especially adolescents, re-
port pain for 3 months or longer (=chronic pain) [1, 4].
Internationally, prevalence rates for musculoskeletal pain
vary between 11 and 38 % [3]. Chronic musculoskeletal
pain is, together with headache and abdominal pain, one
of the most reported pain complaints in adolescents [1, 5].
Although a broad array of medical diagnoses is involved
in adolescent pain conditions, in only 10–30 % of cases a
specific medical disease explaining the pain is identified
[6, 7]. Unexplained musculoskeletal pain is not self-
limiting: persistence rates of pain up to 30–64 % after
4 years have been reported [5, 8, 9]. Pain during adoles-
cence even increases the risk of having a chronic pain syn-
drome in adulthood [5, 10].
The consequences of musculoskeletal pain
Most adolescents function quite well regardless of pain.
Nonetheless, in approximately 40 % of the adolescents
with chronic pain, pain has a disabling impact on daily
functioning [11–13]. Pain can interfere with develop-
mental, school and leisure time activities, and causes ser-
ious psychological distress. It also has an impact on the
adolescent’s families. Primary caregivers report more re-
strictions in social life and more problems with coping
with the adolescent’s pain [14–16]. In addition to the
psychological burden, there is little known about the
financial burden of caring for a child with chronic
pain [17–19].
Although the body of evidence on adult chronic pain
and different rehabilitation treatments is growing, re-
search into adolescents who suffer from chronic pain
complaints is still in its infancy. Rehabilitation care for
adolescents with chronic pain differs from adult care in
several ways. First, in adolescent chronic pain rehabilita-
tion, the family system, and especially influences of the
parents are important to take into account. Parental be-
haviour, such as protective behaviour, has been shown to
influence adolescent’s response to pain. This can result in
greater functional disability, higher school absence and
more depressive symptoms in the children [15, 20–25].
Second, situations and activities that contribute to devel-
oping and maintaining adolescent chronic pain are not
completely similar to those contributing to adult chronic
pain [26, 27]. Third, in adolescents with chronic pain,
prevalence rates of hypermobility (40–55 %) are higher
than in healthy adolescents. Hypermobility as such is not
a problem, but when hypermobility is associated with
complaints, such as pain, it is called joint hypermobility
syndrome (HMS) [28, 29] thereby making HMS a contrib-
uting factor in treating adolescent chronic pain [30–33].
Theoretical framework
According to the fear avoidance model of chronic pain
[34], both fear of pain/movement and catastrophic
thinking about pain can lead to the development and
maintenance of chronic pain problems. Simons and
Kaczynski [35] studied the applicability of the fear avoid-
ance model in the paediatric population and concluded
that the model is applicable, after making some modifi-
cations to account for developmental aspects at child/
adolescent age. Goubert and Simons [25] presented an
interpersonal fear avoidance model of pain, in which the
social context of the adolescent becomes clear.
The implications of these models for a treatment ap-
proach of adolescent CMP is that lowering fear of pain/
movement and accompanying catastrophic thinking
could lower avoidance behaviour and increase functional
ability [34]. Moreover, the interpersonal fear avoidance
model accentuates the necessity to involve the family
system as part of the treatment, in a way that a context
can be created in which the adolescent can change.
Adding the parental influences to the fear avoidance
model is an important difference between the model
for adults and the model for adolescents.
Treatment of chronic pain
Adolescent chronic pain is regarded a complex health
problem that requires a multidisciplinary treatment ap-
proach from a biopsychosocial perspective [17, 36, 37].
This study focuses on multidisciplinary outpatient treat-
ment for adolescents with CMP. Outpatient treatment
currently provided to adolescents in the Netherlands is
mostly based on the principles of Graded Activity (GA).
There is a need for more RCT’s that investigate effect-
iveness of different patient (and parent) interventions in
paediatric CMP [17, 22, 38]. The MRP that is investi-
gated in this study is based on Graded Exposure therapy
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(GE). GE specifically aims at challenging catastrophizing
thoughts and performing feared activities in order to im-
prove functional ability of patients with chronic pain. In
adults with chronic pain this treatment approach is suc-
cessful [39, 40]. The Maastricht University Medical
Centre (MUMC) has recently developed a multimodal
rehabilitation program (MRP), aimed specifically at im-
proving adolescent’s functional ability by reducing pain-
related fear. The Multimodal Rehabilitation Program
consists of 2 different treatment approaches: A graded
exposure module or a combination module of graded
exposure and physical training. Both approaches also in-
clude a parent module. The choice of graded exposure
module or combination module depends on the needs of
the patient (Table 1).
Aims of the study
This study investigates the effectiveness of a multimodal
rehabilitation program (MRP) including Graded Exposure
treatment in reducing functional disability (measured with
the Functional Disability Inventory on short and long
term) in adolescents (12–21 years) with chronic musculo-
skeletal pain compared with care as usual (CAU).
Secondary aims are a) to compare the cost-
effectiveness and cost-utility of both interventions,
also during the follow-up period, an b) to evaluate
the feasibility of working with MRP in terms of
treatment fidelity and patient centeredness.
Methods
Study design and participants
A two group pragmatic randomized controlled trial is
undertaken with adolescents with CMP, with follow-up
assessment at 2, 4, 10 and 12 months after start of treat-
ment. Adolescents will be allocated to either interven-
tion (MRP) or control (CAU) with a ratio 1:1. Patients
who receive an indication for outpatient rehabilitation
treatment will be invited to participate and will be ran-
domized to either usual care (CAU) or the intervention
(MRP) after informed consent is obtained. Parents will
be asked to participate as well.
Estimates for the calculation of the sample size are
based on the primary outcome measure, the Functional
Disability Inventory (FDI). An average FDI total score of
23 (average score obtained from adolescents that were
treated at the Maastricht University Medical Centre in
the year before the start of this study), a standard devi-
ation of 9.2 and an expected mean difference between
intervention and control condition of 5 points on the
total FDI-score were used. A difference of 5 points
equals approximately a 25 % difference in mean FDI
scores between intervention and control group.
Given α = 0.05, two sided testing, a power of 80 %, and
anticipating 15 % loss to follow-up, a sample size of 62
participants per trial-arm was calculated. For two trial
arms, this results in a total sample size of N = 124.
Adolescents will be recruited from 4 centres in The
Netherlands: Maastricht University Medical Centre/
Adelante, Laurentius Hospital Roermond, Revant Re-
habilitation centre Breda and Rijndam Rehabilitation
Centre in Rotterdam. Both treatments offered are embed-
ded in the daily care process in each treatment centre,
with an inclusion period of 1.5 years. Ethical approval for
this trial was granted by the Medical Ethics Committee
Academic Hospital Maastricht/Maastricht University, the
Netherlands, NL47323.068.13/METC13-3-062.
Eligibility criteria
Adolescents with a treatment indication for outpatient
rehabilitation care for treatment of CMP, aged between
12–21 years and with adequate Dutch literacy were eli-
gible for inclusion. Patients will be excluded if there is a)
any suspicion of a medical (orthopaedic, rheumatic or
neurological) disease, that can fully explain the current
level of severity of pain complaints, b) any suspicion of
an (underlying) psychiatric disease that hampers re-
habilitation treatment or c) pregnancy.
Randomization and allocation concealment
Patients will be randomized by minimization after in-
formed consent is obtained. Minimization [41] was
chosen to balance treatment centre, sex and age factors
within the study. To execute the randomization proce-
dures a validated electronic randomization system
(ALEA, offered by the Clinical Trial Centre Maastricht,
CTCM) will be used. Randomization and treatment allo-
cation are completely independent of the study and
blinded for participants including parents and all re-
searchers, including raters and at that moment for care-
givers and the consultant in rehabilitation medicine. After
treatment allocation is revealed, blinding cannot be main-
tained for care givers. Adolescents and parents will be
kept naïve concerning the comparison between the inter-
ventions. The research team remains blinded during the
course of the study. Data collection is also blinded.
Interventions
Contrast between the interventions is found in their the-
oretical basis and point of engagement where the treat-
ment focuses on. Graded Exposure uses principles from
classical conditioning and cognitive therapeutic tech-
niques to systematically reduce pain-related fear and
catastrophic thinking in adolescents with chronic pain
[42]. Graded Activity uses principles of operant condi-
tioning, resulting in rewarding healthy and age
adequate daily functional activities performed by the
adolescent and a stepwise increase of the adolescent’s
activity levels [42].
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Parents are present and are invited to participate in
both the intervention and control condition. However,
in the intervention condition (MRP), parents receive
additional 3 group meetings (the parent module) with
the treatment team (Table 1). Meaning that in the MRP
parents are involved in the treatment of their adolescent
in two ways. They are both present and participate dur-
ing treatment of their child, but additionally they partici-
pate in a separate parent module.
Both treatments are provided by a multidisciplinary
treatment team, including a consultant in rehabilitation
medicine, a physiotherapist or occupational therapist
and a psychologist/behavioural therapist.
Intervention group
In Table 1 the elements of the three modules of the
MRP are described. Graded Exposure aims to increase
healthy behaviour by systematically and gradually expos-
ing adolescents to fear provoking activities and move-
ments. Starting point for this approach is a personal
hierarchy of activities feared by the adolescent. The
Photograph series of Daily Activities – Youth (PHODA-
Youth) [27] is used as a standardized procedure to build
these personal hierarchies. All therapists in the MRP
condition received training on the principles of Graded
Exposure therapy and the treatment protocols, consist-
ing of a workshop and a 3-day training provided by
skilled trainers (with 3 to >15 year experience in Graded
Exposure therapy). Administration of the PHODA-
Youth was part of the 3-day training.
Adolescents in the intervention condition MRP receive
a graded exposure module (7 weeks) or a combination
module (15 weeks) with training and graded exposure.
Their parents receive a parent module (3 meetings). Ado-
lescents with CMP receive the graded exposure module. If
an adolescent is additionally identified (Brighton criteria
including Beighton score, will be used [29, 32, 43]) as hav-
ing pain complaints related to joint hypermobility (HMS),
the combination module will be offered. All parents in the
MRP condition are offered the parent module, which is
organised in the evening hours.
Control group
Currently, treatment of adolescents with chronic pain in
a rehabilitation setting consists of multidisciplinary treat-
ment based on the principles of Graded Activity. Table 2
Table 1 Intervention group: Multimodal Rehabilitation Program, description of the treatment
Graded Exposure module OR Combination module (Graded exposure and physical training)
Phase 1 Intake and PHODA-Youth (60 min)
• Information about cognitive, behavioral and
psychophysiological aspects of pain complaints
• Description of family system and situation
• Identification of activities that are being avoided, and
accompanying cognitions
Phase 2 Education (60 min)
• Explanation of treatment rationale
• Explanation of treatment
• Alternative explanation for persistence of pain complaints
• Personal fear avoidance model
Phase 3 Graded Exposure treatment sessions (12 × 60 min)
• Systematic exposure to fear provoking activities and
movements
• Behavioral experiments
• Generalization and relapse prevention
Phase 1 Intake, PHODA-Youth, and physical examination (60 min)
• Information about cognitive, behavioral and psychophysiological aspects
of pain complaints
• Description of family system and situation
• Identification of activities that are being avoided, and accompanying
cognitions
• Physical examination of strength, balance and propriocepsis.
Phase 2 Education Graded Exposure and training (60 min)
• Explanation of treatment rationale
• Explanation of treatment: Training and graded exposure sessions
• Alternative explanation for persistence of pain problems
• Explanation of physical training
• Personal fear avoidance model
Phase 3 Training (16x120 min)
• Training (hydrotherapy if possible), focusing on aerobic capacity, muscle
strength, core stability, propriocepsis
• Homework (training exercises)
Phase 4 Graded Exposure treatment sessions (6x 60 min)
• If necessary: repetition of treatment rationale
• Systematic exposure to fear provoking activities and movements
• Behavioral experiments
• Generalization and relapse prevention
AND
Parent module
Phase 1 Medical education and treatment rationale
• Explanation of treatment rationale
• Explanation of treatment
• Alternative explanation for persistence of pain complaints
• Personal fear avoidance model for their child
Phase 2 The role of pain within the family system
• Explanation of the influence of pain on the family system and interaction between parents and child
• Tools to support the child in creating and maintaining behavioral change
Phase 3 Generalization and relapse prevention
• Identifying and recognizing risky situations that can trigger relapse
• Preventing relapse by making plans
Dekker et al. BMC Musculoskeletal Disorders  (2016) 17:317 Page 4 of 11
presents the main treatment elements of GA. GA aims
to increase healthy behaviour by employing operant
learning principles such as encouraging desired behav-
iours [42]. The treatment consists of a time contingent
and stepwise increase in the level of functioning, despite
complaints of pain [44]. Duration of the care as usual
treatment varies between 9 and 16 weeks. This variation
exists because each collaborating treatment centre has
developed its own specific treatment protocol, also de-
pending on the practical and logistic possibilities of the
treatment centre. Content of the treatment programmes
is generally similar and principal discriminative from the
content of the experimental intervention (MRP).
Outcome measures
PedIMMPACT recommendations were followed when
choosing outcome domains and in the selection of
measurement instruments for this study [45]. Details of
measurement instruments can be found in Table 3. As-
sessments will be performed at baseline (before start of
treatment) and at 2, 4, 10 and 12 months after start of
treatment. Primary outcome measure is adolescent’s
functional disability (FDI) [46, 47]. Secondary outcome
measures are adolescent fear of pain (FOPQ-C) [48],
perceived harmfulness (PHODA-Youth) [27], pain cata-
strophizing (PCS-C) [49, 50], pain intensity (VAS) [51],
depressive symptoms (CDI) [52] and pain specific quality
of life (QLA-CP) [53], and parent perceived functional
disability (FDI-P) [46, 47], fear of pain (FOPQ-P) [48],
pain catastrophizing (PCS-P) [50], adult responses to
children’s symptoms (ARCS) [54].
Other study parameters
Demographic variables will be measured at baseline.
These variables include age, sex, educational level and
school absence, family composition, ethnic background.
Variables related to chronic pain that will be measured
include: onset and duration of pain complaints, location
of pain complaints, course of the complaints, and (if
applicable) medication use.
Costs measurement
To evaluate the economic consequences, the interven-
tion costs, other health care costs, patient and family
costs, and productivity losses will be assessed. Patient
and family costs include out-of-pocket costs, such as
costs for informal care and extra expenses. Productivity
losses (for adolescents and parents) are based on the
days absent from work or school because of the pain.
At baseline, total costs will be inventoried 3 months
retrospective. During the trial period (12 months)
monthly cost-diaries will be used after the end of treat-
ment. For addressing cost-effectiveness of interventions,
the cost-diary method might be a successful method
[55]. Both the parents and the adolescents will be asked
to provide information about health care utilization and
school absenteeism/productivity losses. If the adolescents
are 18 years or older, they may choose to fill out the cost
diary themselves, below 18 years it is recommended they
complete the cost diary together with their parents.
Generic health related quality of life was measured
with the EQ-5D-Y [56]. The EQ-5D-Y is a self-report
measure of health related quality of life. QALY’s can be
calculated by means of the applying a tariff to obtain a
weighted health state index. The adult tariff will be used
for the Youth-version of the questionnaire, since no
youth-tariff is available.
Process evaluation
To evaluate treatment fidelity, a process evaluation will
be performed. The Method of Assessing Treatment De-
livery (MATD) [57] will be applied, including audio or
videotaping treatment sessions to assess protocol adher-
ence. There will be a focus on protocol adherence of the
therapists in the MRP condition and a contamination
check will be performed to evaluate whether treatments
provided in both arms of the trial were indeed different
from each other. For treatment fidelity to be adequate,
at least 70 % of essential treatment elements must have
occurred in order to satisfy the requirements for proto-
col adherence. Furthermore, maximally 10 % of prohib-
ited treatment elements may have occurred to satisfy the
Table 2 Control group: Care as Usual, description of the
treatment
Phase 1 Inventory of the problem
• Anamnesis
• Estimation of motivation for rehabilitation treatment
• Physical examination
• Identification of maintaining factors for the pain problems
• Analysis of activities
Phase 2 Problem analyses
• Ordering information from inventory
• Providing an explanatory model for the pain problem
• Treatment plan
Phase 3 Education
• Exploring willingness to change behaviour
• Changing behaviour despite pain
Phase 4 Choosing activities
• Choosing activities on a functional level
• Determining treatment goals (SMART)
Phase 5 Determining baseline (Pain contingent functioning)
• Determining baseline level of functional activities (min 3–5
measurement moments)
Phase 6 Determining goal and scheme to increase activity
• Starting level below baseline
• Scheme for time contingent increase in activities
• Establishing treatment goals
Phase 7 Executing scheme
• Time contingent increase of activities
• Encouragement of successful behaviour
• Generalization at home and school
Phase 8 Generalization and evaluation
• Applying in daily situations
• Evaluation of treatment
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Table 3 Primary and secondary outcome measuresa
Primary outcome Measurement instrument Time points of measurement
Functional disability [46, 47] Functional Disability Inventory (FDI) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Self-report measure for perceived difficulty in performing activities
at school, at home and in recreational or social interactions.
15 Items rated on a five-point scale (0–4). Total scores range 0–60
with a higher scores indicating greater disability.
Valid and reliable measure for assessing pain related disability in adolescents.
Secondary outcomes Measurement instrument Time points of measurement
Fear of pain [48] Fear of Pain Questionnaire (FOPQ-C) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Self-report measure to assess pain-related fear in adolescents with
chronic pain. 24 items rated on a five-point scale (0–4). Total scores
range 0–96 with a higher score indicating more fear. Consists of
subscales 1) Fear of Pain and 2) Avoidance of activities.
Psychometric properties of the English version are good.
Perceived harmfulness [27] PHODA-Youth Baseline, 8 weeks, 16 weeks,
10 and 12 months
Measures perceived harmfulness of physical and social activities
and can be used to create a hierarchy of fearful activities.
51 photographs are rated on a scale 0–10 (steps 0.1). The higher
a photo is ranked, the more harmful the adolescent thinks executing
the activity is. Consists of subscales 1) activities of daily living, 2)
intensive physical activities and 3) social activities.
Psychometric qualities are good.
Pain Catastrophizing [49] Pain Catastrophizing Scale (PCS-C) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Self-report measure of catastrophic thinking about pain. Frequency
of feelings and thoughts adolescents may experience when they
are in pain are measured.
13 items rated on a five-point scale (0–4). Total scores range 0–52
with higher scores indicating more catastrophic thinking. Consists
of subscales 1) Rumination, 2) Magnification, and 3) Helplessness.
Reliability and validity are good.
Depressive symptoms [52] Child Depression Inventory (CDI) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Self-report measure of depressive symptoms in children and adolescents.
27 items rated on a three-point scale (0–2). Total scores range 0–54
with higher scores indicating more depressive symptoms. Consists
of subscales 1) Negative mood, 2) Interpersonal problems, 3)
Ineffectiveness, 4) Negative self-esteem, and 5) Anhedonia.
Dutch version demonstrates good reliability and validity.
Pain specific quality of life [53] Quality of Life in Adolescent with Chronic Pain (QLA-CP) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Self-reported pain-specific quality of life measure for adolescents
with chronic pain.
44 items in 6 domains, 1) Psychological functioning, 2) Functional
status, 3) Physical status, 4) Social functioning, 5) Satisfaction with
life in general, and 6) Satisfaction with health. A high score on
each domain of the questionnaire represents a better quality of life.
Internal consistency and construct validity have shown to be adequate.
Pain Intensity [51] Visual Analogue scale (VAS) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Self-report measure of pain intensity. Sliding scale where the ends
of the line represent the extreme limits of pain intensity (no pain at
all and worst pain imaginable). Average VAS score is taken of pain
at this moment, worst and least pain in last week.
Reliable method in children above 8 years old. Sound psychometric
properties and clinical utility.
Functional Disability Inventory – Parent report (FDI)
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Table 3 Primary and secondary outcome measuresa (Continued)
Parent perceived Functional
Disability [46, 47]
Baseline, 8 weeks, 16 weeks,
10 and 12 months
Measure of parent perceived functional disability of their child.
15 items rated on a five-point scale (0–4). Total scores range 0–60
with higher scores indicating greater parent-perceived difficulty in
performing activities.
Parent perceived Fear of Pain [48] Fear of Pain Questionnaire – Parent report (FOPQ-P) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Parent proxy report measure to assess parents perception of their
childs pain-related fear experience.
23 items rated on a five-point scale (0–4). Total scores range 0–92 with
higher scores indicating a higher parent perceived fear. Consists of
subscales 1) fear of pain, 2) avoidance of activities, and 3) School avoidance.
Psychometrically sound measure with strong internal consistency,
good construct and criterion validity.
Parental Pain catastrophizing [50] Pain Catastrophizing Scale – Parent report (PCS-P) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Measures parental catastrophizing about their child’s pain.
13 items rated on a five-point scale (0–4). Total scores range 0–52
with higher scores indicating more catastrophic thinking by the
parents.
Psychometric properties are good to very good.
Adult response to children’s
symptoms [54]
Adult response to children’s symptoms scale (ARCS) Baseline, 8 weeks, 16 weeks,
10 and 12 months
Parent self-report measure of a range of parental responses to pain of their child.
29 items rated on a five-point scale (Never-always). Consists of
subscales 1) Protective responses, 2) minimizing responses (criticizing
or downplaying the pain) and 3) monitoring/encouraging responses
(encouraging activity while monitoring symptoms)
Valid instrument for assessing parents’ responses to children’s pain
for diverse chronic pain symptoms.
Other study parameters Used in economic evaluation and process evaluation
Costs (economic evaluation) [55] Cost diary After treatment each month
until month 12.
Health care utilization, school absence and productivity losses are recorded.
Generic health related quality of life
(economic evaluation) [56]
EQ-5D-Y Baseline, 8 weeks, 16 weeks,
10 and 12 months
Generic self-report measure of health related quality of life.
5 Items, scored on three levels: no problems, moderate problems,
severe problems. Contains domains 1) mobility, 2) self-care, 3) usual
activities, 4) pain/discomfort, and 5) anxiety/depression. 1 visual
analogue scale to rate their own health between 0 and 100 (best
health state).
Satisfaction/patient centeredness
(Process evaluation) [58]
Giving Youth A Voice Questionnaire (GYV-20) 16 weeks
The instrument has 4 themes, 1) supportive and respectful relationships,
2) Information sharing and communication, 3) Supporting independence
and 4) Teen-centred service. Each item is formulated as a question,
starting with ‘How much do the people who work with you…’ and
then a description of a specific action or behaviour of the health care
professional is given. Response options range from 1–7, with a ‘not
applicable’ category added. Scale scores can be calculated as the mean
of the ratings for the items in the scale.
Satisfaction/family centeredness
(Process evaluation) [59, 60]
Measure of Processes Of Care – Parent form – Short form (MPOC-P-20) 16 weeks
20 items, scored on a scale 1–7. Consists of 5 scales, 1) Enabling and
Partnership, 2) Providing General Information, 3) Providing Specific
Information about the Child, 4) Coordinated and Comprehensive Care
for the Child and Family and 5) Respectful and Supportive Care. Responses
to each item are converted to a mean for each scale. No total score
can be calculated.
Treatment expectations of children
(Process evaluation) [61]
Credibility/Expectancy Questionnaire (CEQ-Adolescent) Baseline
On the 11 items (5 on credibility, 6 on expectancy) can be answered
on a 9-point scale from ‘totally not’ to ‘totally’. Total scores are a sum
score of the individual items and ranges from 11 to 99.
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requirements for contamination. Furthermore, satisfac-
tion with the received treatment and the degree of ado-
lescent/family centeredness of the offered interventions
will be measured with the Giving Youth a Voice Ques-
tionnaire (GYV-20) [58] and Measure of Processes of
Care Parent Version short form (MPOC-P-20) [59, 60].
Finally, a comparison will be made between treatment
expectation (measured with the Credibility/Expectancy
Questionnaire, CEQ-m) [61].
Data-analysis
Statistical analysis
All analysis will be performed on the basis of the
“intention-to-treat principle”. Descriptive statistics for
demographic and clinical characteristic for both groups
(MRP and CAU) and the total group will be used. An in-
ventory of missing data will be made and if necessary an
imputation strategy will be chosen.
Effect evaluation
Differences after 8 and 16 weeks of treatment will be
calculated (short term outcomes), as well as long term
outcomes at 10 and 12 months. A linear mixed models
approach for calculating differences between baseline
and the final follow-up at 12 months will be used. This
method used both fixed and random effects in the same
analysis. It handles naturally unbalanced data as e.g. un-
even spacing of repeated measures and allows analysing
the relationship of predictor covariates with the
dependent variable (FDI-score). It also accounts success-
fully for the observed pattern of dependences in the
measurements. Appropriate covariates (for the primary
outcome potential important imbalances in baseline var-
iables) will be identified in a univariate regression ana-
lysis. Before starting the analysis the baseline score of
the dependent variable FDI-score and all identified co-
variates will be centred by subtracting the group mean.
In a first step a fixed effects model will be run and in a
second step random effects will be added. Insignificant
covariates will then be stepwise removed from the
model. Model fit will be assessed with the help of the
Bayesian Information Criterion (BIC) and the -2Log like-
lihood [62].
Economic evaluation
In the economic evaluation costs and effects of the inter-
vention condition (MRP) and the control condition
(CAU) will be calculated and compared, using a societal
perspective. Total costs will be estimated using a
bottom-up approach, where information on each elem-
ent of service use is multiplied by an appropriate stan-
dardized unit cost and summed to provide and overall
total cost. For the cost valuation, standardized cost
prizes will be used from the Dutch manual for cost ana-
lysis in health care research [63]. Productivity losses will
be calculated based on the Human Capital Approach.
At baseline resource use prior to the study will be
measured, to allow this use as a covariate in the analysis,
which enables correction for possible cost differences at
baseline [64]. Cost per patient year (= participant year)
will be calculated.
Intended, both a cost-effectiveness analysis (CEA) and
a cost-utility analysis (CUA) will be performed. For the
CEA the cost-effectiveness ratio will be stated in terms
of cost per 5 points of improvement on the Functional
Disability Inventory (FDI). For the CUA the cost-utility
ratio will be stated in terms of cost per Quality Adjusted
Life Year (QALY) gained, as measured by the EQ5D-Y
[65]. Bootstrap re-sampling techniques will be used to
test for differences and uncertainty in cost and effects
between MRP and CAU.
Process evaluation
To evaluate treatment fidelity, audio or video recordings
will be analysed of treatment sessions of both interven-
tions conditions [42]. From these recordings, a random
sample will be taken for analysis. The recordings are
rated for protocol adherence, contamination, and differ-
entiation [42]. Ratings will be performed by 2 raters,
independent of this trial and blind to the study hypoth-
eses. To enable rating, a Treatment Fidelity Checklist is
developed where raters can indicate whether a
treatment-element took place or not [57]. The percent-
age of deviation from the allowed treatment-elements is
compared between the intervention and control condi-
tion by logistic regression analysis.
Table 3 Primary and secondary outcome measuresa (Continued)
Treatment expectations parents
(Process evaluation) [61]
Credibility/Expectancy Questionnaire (CEQ-Parent) Baseline
On the 11 items (5 on credibility, 6 on expectancy) can be answered
on a 9-point scale from ‘totally not’ to ‘totally’. Total scores are a sum
score of the individual items and ranges from 11 to 99.
Joint Hypermobility Syndrome
(HMS) [29, 32, 43]
Birghton Criteria Baseline
To identify adolescents with HMS the Brighton criteria, including a
Beighton score will be used. A cut-off value of ≥5 will be used for
hypermobility.
aNot for all measures detailed information about reliability and validity was available
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The data from the Credibility/expectancy question-
naire and the measures of patient/family centeredness
(GYV-20 and MPOC-20) of the provided treatment will
be used to evaluate differences in credibility and expect-
ancy at the start of the treatment, and treatment satis-
faction at the end of treatment.
Discussion
Research on treatment options for adolescents with
CMP is still in its infancy, but multidisciplinary treat-
ment for this patient group seems to be a promising
treatment approach. A limited number of studies have
been performed to study the effectiveness of multidisciplin-
ary treatments on improving functional ability [66–70]. Al-
though several pre- and post-treatment comparisons have
been performed, to our knowledge only few studies have
compared different treatment options with each other. An-
other important element in adolescent treatment is the par-
ticipation of parents, again, with limited evidence available
on the effectiveness of parental interventions [17, 22, 38].
There is an urgent need for more research. Therefore,
a pragmatic multicentre randomized controlled trial
(RCT) was established to compare a new multimodal
rehabilitation program with care as usual. For this study
a more pragmatic approach is chosen. Schwarts and
Lellouch [71] use the term ‘pragmatic’ to describe
studies designed to choose between options of care,
as opposed to ‘explanatory’ studies that test causal re-
search hypotheses. Our aim is to compare the new
treatment approach to existing practice to determine
whether or not the new approach can be added to
the treatment options existing presently. This approach
led to some design choices that were made to maximize
the applicability of the results to usual care settings.
To include a wide range of participants eligibility criteria
are focused on the inclusion of all adolescent participants
that would normally receive an indication for rehabilita-
tion treatment. This should lead to the inclusion of a
heterogeneous group of participants, very similar to the
patients that are seen in current clinical practice.
Adolescents aged 12–21 years old are eligible to par-
ticipate in the trial. Paediatric rehabilitation services are
in principle provided up to the age of 18 years old. Most
studies on treatments for adolescents include partici-
pants up to the age of 18 years old. The range of 12–21
years was chosen according to Kaplan’s [72] definition of
adolescent life stage, starting with early adolescence at
12 years old, ending of late adolescence at 21 years old.
Furthermore, research has shown that up to the age of
21 years, brain functions are still developing [73]. There-
fore, interpretation of cognitive and behavioural pro-
cesses can still be sensitive to change and can best be
seen in to context of adolescence instead of adulthood.
Additionally, in the Netherlands only 20 % of the 15–20
year olds are part of the working population, so for the
largest part of this age group, their daily social and phys-
ical activities are more in line with the school-attending
adolescents than with the working adult population.
To our knowledge, 2B Active is one of the first studies
performing an economic evaluation on outpatient treat-
ment and follow up, focussing both on the cost of the
intervention itself and on patient and family costs. No
measurement instrument existed that measured both
adolescent and parent costs of the rehabilitation trajec-
tory and follow-up. Therefore, a cost diary was devel-
oped to measure both medical consumption and
productivity losses (work and school absenteeism) after
completion of the rehabilitation program.
To summarize, several design choices that have been
made may influence the balance between internal valid-
ity and external validity of the study. By studying the
new intervention in a pragmatic way and in the setting
in which the MRP treatment is intended to be offered,
the results will be more generalizable to daily practice of
rehabilitation care. Including a heterogeneous group of
patients and analysis according to ITT may lead to re-
sults that are not over-estimated since real practice daily
difficulties are incorporated in the trial results.
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